CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana. The Medicago method to manufacture CoVLP is a "molecular farming" technology regarded as rapid, low-cost, and safe. It has been proposed specifically for production of COVID-19 vaccines. As of January 2021, the Medicago CoVLP vaccine candidate was in a Phase II-III clinical trial in Canada and the United States, involving 30,918 participants.